High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma
Alexander T. Faje, Ryan J. Sullivan(Dana-Farber Cancer Institute), Christine Freedman(Massachusetts General Hospital), Krista M. Rubin(Massachusetts General Hospital), Justine V. Cohen(Massachusetts General Hospital), Donald P. Lawrence(Massachusetts General Hospital), Riley Fadden(Massachusetts General Hospital), Keith T. Flaherty(Cancer Research Center)
Cited by 481
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k